Advertisement

International Journal of Hematology

, Volume 109, Issue 2, pp 154–161 | Cite as

Characteristics and prognosis of patients with non-immunoglobulin-M monoclonal gammopathy of undetermined significance: a retrospective study

  • chihiro Kuwabara
  • Yukie Sakuma
  • Ayaka Kume
  • Yuri Tamura
  • Ryo Shimizu
  • Rie Iwai
  • Akihiro Ishii
  • Hiroaki TanakaEmail author
Original Article

Abstract

Non-immunoglobulin (Ig)-M monoclonal gammopathy of undetermined significance (MGUS) is a precursor lesion with the potential to evolve into a malignant plasma cell neoplasm. The prevalence of MGUS differs by ethnicity and is lower in the Japanese population than in the Western population. However, there is limited evidence about the clinical course of MGUS in Asian races. The present study aims at elucidating the clinical course and prognosis of Japanese patients with non-IgM MGUS in the clinical setting. We retrospectively examined 1009 patients with non-IgM MGUS identified by screening procedures. The median overall survival of these patients was > 20 years, and only one-fifth patients died of plasma cell neoplasms. The cumulative incidence of plasma cell neoplasms requiring treatment was 19%. Multivariate analysis revealed that immunoparesis and female gender were independent factors affecting treatment requirement. Although the characteristics and clinical course of patients with non-IgM MGUS obtained in this study were found to be essentially similar to those of previous studies, we report here for the first time that female gender is a significant independent factor for requiring treatment.

Keywords

Non-IgM monoclonal gammopathy Monoclonal gammopathy of undetermined significance Multiple myeloma Immunoparesis Female 

Notes

Acknowledgements

The authors would like to thank Yasunori Sato of the Clinical Research Center and Chikako Ohwada of the Department of Hematology, Chiba University Hospital, Chiba, Japan, for her valuable advice on statistics and research design.

Compliance with ethical standards

Conflict of interest

The authors disclose no potential conflict of interest.

References

  1. 1.
    McKenna KR, Kuehl WM, Harris NL, Coupland RW, Fend F. Plasma cell neoplasms. In: Swerdlow SH, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised fourth edition. Lyon: IARC; 2017. pp. 241–58.Google Scholar
  2. 2.
    Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15:e538-48.CrossRefGoogle Scholar
  3. 3.
    Landgren O, Gridley G, Turesson I, Caporaso NE, Goldin LR, Baris D, et al. Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States. Blood. 2006;107:904–6.CrossRefGoogle Scholar
  4. 4.
    Iwanaga M, Tagawa M, Tsukasaki K, Kamihira S, Tomonaga M. Prevalence of monoclonal gammopathy of undetermined significance: study of 52,802 persons in Nagasaki City, Japan. Mayo Clin Proc. 2007;82:1474–9.CrossRefGoogle Scholar
  5. 5.
    Mateos MV, Hernandez MT, Giraldo P, de la Rubia J, de Arriba F, Lopez Corral L, et al. Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma. N Engl J Med. 2013;369:438–47.CrossRefGoogle Scholar
  6. 6.
    Iida S. Mechanisms of action and resistance for multiple myeloma novel drug treatments. Int J Hematol. 2016;104:271–2.CrossRefGoogle Scholar
  7. 7.
    Rajkumar SV, Larson D, Kyle RA. Diagnosis of smoldering multiple myeloma. N Engl J Med. 2011;365:474–5.CrossRefGoogle Scholar
  8. 8.
    Larsen JT, Kumar SK, Dispenzieri A, Kyle RA, Katzmann JA, Rajkumar SV. Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma. Leukemia. 2013;27:941–6.CrossRefGoogle Scholar
  9. 9.
    Hillengass J, Fechtner K, Weber MA, Bauerle T, Ayyaz S, Heiss C, et al. Prognostic significance of focal lesions in whole-body magnetic resonance imaging in patients with asymptomatic multiple myeloma. J Clin Oncol. 2010;28:1606–10.CrossRefGoogle Scholar
  10. 10.
    Tanaka H, Sakuma Y, Ikeda H, Shimizu R, Sugita Y, Iwai R. Characteristics and prognosis of patients with immunoglobulin M monoclonal gammopathy. J Clin Exp Hematop. 2017;57:47–53.CrossRefGoogle Scholar
  11. 11.
    Kitamura M, Yamaguchi H, Murakawa K, Murao T, Iizuka Y. Screening for multiple myeloma using routine laboratory test results. Clin Biochem. 1982;15:17–21.CrossRefGoogle Scholar
  12. 12.
    Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013;48:452–8.CrossRefGoogle Scholar
  13. 13.
    Kyle RA, Therneau TM, Rajkumar SV, Offord JR, Larson DR, Plevak MF, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med. 2002;346:564–9.CrossRefGoogle Scholar
  14. 14.
    Perez-Persona E, Vidriales MB, Mateo G, Garcia-Sanz R, Mateos MV, de Coca AG, et al. New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells. Blood. 2007;110:2586–92.CrossRefGoogle Scholar
  15. 15.
    Turesson I, Kovalchik SA, Pfeiffer RM, Kristinsson SY, Goldin LR, Drayson MT, et al. Monoclonal gammopathy of undetermined significance and risk of lymphoid and myeloid malignancies: 728 cases followed up to 30 years in Sweden. Blood. 2014;123:338–45.CrossRefGoogle Scholar
  16. 16.
    Rajkumar SV, Kyle RA, Therneau TM, Melton LJ, Bradwell AR, Clark RJ, et al. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood. 2005;106:812–7.CrossRefGoogle Scholar
  17. 17.
    Kristinsson SY, Tang M, Pfeiffer RM, Bjorkholm M, Blimark C, Mellqvist UH, et al. Monoclonal gammopathy of undetermined significance and risk of skeletal fractures: a population-based study. Blood. 2010;116:2651–5.CrossRefGoogle Scholar
  18. 18.
    Thorsteinsdottir S, Lund SH, Lindqvist EK, Thordardottir M, Sigurdsson G, Costello R, et al. Bone disease in monoclonal gammopathy of undetermined significance: results from a screened population-based study. Blood Adv. 2017;1:2790–8.CrossRefGoogle Scholar
  19. 19.
    Piot JM, Royer M, Schmidt-Tanguy A, Hoppe E, Gardembas M, Bourree T, et al. Factors associated with an increased risk of vertebral fracture in monoclonal gammopathies of undetermined significance. Blood Cancer J. 2015;5:e345.CrossRefGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2018

Authors and Affiliations

  1. 1.Department of HematologyAsahi General HospitalAsahiJapan
  2. 2.Clinical Research Support CenterAsahi General HoIspitalChibaJapan
  3. 3.Department of Transfusion MedicineAsahi General HospitalChibaJapan

Personalised recommendations